summit 2017aacr draft 31-mar-2017 final - … summit_2017aacr_slides.pdfsummit ‘basket’ study...
TRANSCRIPT
NeratinibinHER2- orHER3-mutantsolidtumors:SUMMIT,aglobal,multi-histology,open-label,phase2‘basket’studyDavidM.Hyman,1 SarinaPiha-Paul,2 JordiRodon,3 CristinaSaura,3 GeoffreyI.Shapiro,4 DavidI.Quinn,5VictorMoreno, 6 IngridMayer,7CarlosArteaga,7 ValentinaBoni,8 EmilianoCalvo,8 ShereneLoi,9 A.CraigLockhart,10 LillianM.Smyth,1 JosephErinjeri,1MaurizioScaltriti,1 FJavierCarmona,1 GaryUlaner,1 JeanTorrisi,1 Juber Patel,1 Jiabin Tang,1 Fanli Meng,1 Duygu Selcuklu,1HelenWon,1 NancyBouvier,1MichaelF.Berger,1 RichardE.Cutler,Jr.,11 FengXu,11 AnnaButturini,11 LisaD.Eli,11 GraceMann,11CynthiaFarrell,11Alshad S.Lalani,11 RichardBryce,11 Funda Meric Bernstam,2 JoséBaselga,1 DavidB.Solit1
1MemorialSloanKetteringCancerCenter,NewYork,NY,USA;2MDAndersonCancerCenter,Houston,TX,USA;3Valld’Hebron UniversityHospital,Barcelona,Spain; 4DanaFarberCancerInstitute,Boston,MA,USA;5USCNorrisComprehensiveCancerCenter,LosAngeles,CA,USA;6STARTMadridFundación JímenezDíaz,Madrid,Spain;7Vanderbilt-IngramCancerCenter,Nashville,TN,USA;8STARTMadridGroup,Madrid,Spain 9PeterMacCallumCancerCentre,Melbourne,Victoria,Australia;10WashingtonUniversityinSt.LouisSchoolofMedicine,St.Louis,MO,USA;11PumaBiotechnologyInc,LosAngeles,CA,USA
OralCT001
HER2(ERBB2)mutations• SubsetsofsomaticHER2mutationsareseenatrelativelylowfrequenciesacrossmultipletumortypes
• Activating HER2mutationsresultinconstitutivekinasesignaling,activationofgrowthpromoting/survivalpathways,oncogenictransformationandenhancedtumorgrowthinpreclinicalmodels
2cBioportal.orgaccessedon16March2017
HER2mutations
Activationofdownstreamsignaltransductionpathwaysandtumorgrowthsurvival
P P
NeratinibinHER2-mutant cancer• Neratinibisanoral,irreversiblepan-HERtyrosinekinaseinhibitor• Neratinibleadstopotentinhibitionofintracellularsignaling,cellproliferationandcolonyformation
ofHER2-mutanttumorcelllinesinvitro1,2
• HER2-mutantalleleshavedistinctdifferentialsensitivitytoneratinib
1Boseetal.CancerDiscovery2013:3;224–2372Carmonaetal.CancerRes2016:76(14Suppl);abst 298 3
-3-2-10
0
5 0
1 0 0
H K I-2 7 2 c o n c e n tra t io n (L o g µ M )
Cel
l via
bilit
y (%
)
Neratinib(LogµM)
-3-2-10
0
5 0
1 0 0
H E R 2 V 7 7 7 L
W T
H K I-2 9 2 c o n c e n tra t io n (L o g µ M )
Cel
l via
bilit
y (%
)
H E R 2 L 7 5 5 S
Y V M A in s
D 7 6 9 HI7 6 7 M
Sensitivity
0 –1 –2 –3
100
50
0
Cellviab
ility(%
)
AmplifiedwildtypeD769HI767ML755SV777LYVMAins
2500
2000
1500
1000
500
0WT V777L D769H V8421 L755Sdel.755–9 R678Q G309A
Meancolonyco
unt
VehicleLapatinibNeratinib
SUMMIT‘basket’studydesign
4
Solidtumors(NOS)
Endometrial
Gastroesophageal
Ovarian
Colorectal
Bladder/urinary tract
Solidtumors(NOS)
Neratinibmonotherapy
HER2 orHER3mutations(documentedbylocaltesting)
Primaryendpoint• Objectiveresponserateatweek8(ORR8)
Secondaryendpoints• ORR(confirmed)• Clinicalbenefitrate(CBR)• Progression-freesurvival(PFS)• Safety• Biomarkers
Simon2-stagedesign• If≥1responseinfirstevaluable7patients,expandcohorttoStage2(N=18)• If≥4responsesinStage2,expandorbreakout
Tumorassessments• RECISTv1.1(primarycriteria)• PETresponse
Statisticalmethods• ORR8,ORR,CBR:associated95%CI• MedianPFS:Kaplan-Meierestimatewith95%CI
Breast
Cervical
Biliarytract
Lung
Datacut-off:10-Mar-2017NOS=nototherwisespecified
• FFPEtumors(archivalorfreshpre-treatmentbiopsies)retrospectivelysequencedcentrallyusingNGS(MSK-IMPACT)• PlasmacfDNA (pre-treatment)retrospectivelysequencedcentrallyusinga HER2single-genehybridcaptureresearchassay(MSKCC)
HER2-mutanttumors
HER3-mutanttumors Closed
Open
Enrollment
EnrollmentbytumortypeNeratinib monotherapy(n=141)
HER2-mutationpositive
Lungcancer 26(18.4)
Breastcancer 25(17.7)
Bladder/urinarytractcancer 16(11.3)
Solidtumors(NOS) 15(10.6)
Colorectalcancer 12(8.5)
Biliarytractcancer 9(6.4)
Endometrialcancer 7(5.0)
Cervicalcancer 5(3.5)
Gastroesophagealcancer 5(3.5)
Ovariancancer 4(2.8)
HER3-mutationpositive
Solidtumors(NOS) 17(12.1) 5
Baselinedemographics
6
PatientcharacteristicsHER2mutant
(n=124)HER3mutant
(n=17)Total
(n=141)
AgeMedian(range),years<65years,n(%)≥65years,n(%)
61(30–83)81(64.8)43(34.7)
66(39–82)7(43.8)10(58.8)
61(30–83)88(62.4)53(37.6)
Gender,n(%)FemaleMale
79(63.7)45(36.3)
13(76.5)4(23.5)
92(65.2)49(34.8)
ECOGperformance status,n(%)012
36(29.0)83(66.9)5(4.0)
2(11.8)12(75.6)3(17.6)
38(27.0)95(67.4)8(5.7)
Priorsystemiclines,n(%)AnyNone12≥3
120(96.8)4(3.2)
33(26.4)29(23.4)58(46.4)
17(100)0(0)1(6.3)
12(70.6)4(25.0)
137(97.0)4(2.8)
34(24.1)41(29.1)62(44.0)
Mediantimefrommetastasistoenrollment,years(range) 1.02(0.0–15.0) 1.13(0.3–4.5) 1.03(0.0–15.0)
Patientdisposition
9
ParameterHER2mutant
(n=124)HER3mutant
(n=17)Total
(n=141)
Patientscontinuingontreatment,n(%) 10 0 10
Treatmentdiscontinuation,n(%)DeathDiseaseprogressionAdverse eventWithdrawalofconsentInvestigatorrequestLosttofollow-upOther
114(91.9)2(1.6)
88(71.0)5(4.0)4(3.2)5(4.0)1(0.8)9(7.2)
17(100.0)1(5.9)
16(94.1)0(0.0)0(0.0)0(0.0)0(0.0)0(0.0)
131(92.9)3(2.1)
104(73.8)5(3.5)4(2.8)5(3.5)1(0.7)9(6.4)
Subjectsendedstudy,n(%)DeathWithdrawalofconsentLosttofollow-upOther
81(65.3)70(56.5)5(4.0)5(4.0)1(0.8)
15(88.2)12(70.6)2(12.5)1(6.3)0(0.0)
96(68.1)82(58.2)7(5.0)6(4.3)1(0.7)
Efficacysummary
19
HER2mut HER3mut
Breast(n=25)
Bladder(n=16)
Lung(n=26)
Colorectal(n=12)
Biliarytract(n=9)
Cervical(n=5)
NOS(n=17)
ORRatweek8,n (%)[95%CI]
8(32.0)[14.9–53.5]
0(0.0)[0.0–20.6]
1(3.8)[0.1–19.6]
0(0.0)[0.0–26.5]
2(22.2)[2.8–60.0]
1(20.0)[0.5–71.6]
0(0.0)[0.0–20.6]
ORR,n(%)[95%CI]
6(24.0)[9.4–45.1]
0(0.0)[0.0–20.6]
1(3.8)[0.1–19.6]
0(0.0)[0.0–26.5]
0(0.0)[0.0–33.6]
1(20.0)[0.5–71.6]
0(0.0)[0.0–20.6]
Clinicalbenefitrate,n(%)[95%CI]
10(40.0)[21.1–61.3]
3(18.8)[4.0–45.6]
11(42.3)[23.4–63.1]
1(8.3)[0.2–38.5]
3(33.3)[7.5–70.1]
3(60.0)[14.7–94.7]
2(11.8)[1.6–38.3]
MedianPFS,months(95%CI)
3.5(1.9–4.3)
1.8(1.7–3.5)
5.5(2.7–10.9)
1.8(1.4–1.9)
2.8(0.5–3.7)
20.1(0.5–NA)
1.7(1.4–2.0)
Incidenceoftreatment-emergentadverseevents(≥10%)Neratinibmonotherapy(N=141)
Adverse event,n(%) Anygrade Grade≥3
Diarrhea 104(73.8) 31(22.0)Nausea 61(43.3) 3(2.1)Vomiting 58(41.1) 3(2.1)Constipation 49(34.8) 2(1.4)Fatigue 45(31.9) 5(3.5)Decreasedappetite 40(28.4) 1(0.7)Abdominalpain 33(23.4) 7(5.0)Anemia 22(15.6) 10(7.1)Dyspnea 18(12.8) 5(3.5)Dehydration 17(12.1) 8(5.7)Aspartateaminotransferaseincreased 15(10.6) 5(3.5)Asthenia 15(10.6) 1(0.7)Weightdecreased 15(10.6) 0 20
Characteristicsofdiarrhea
Adverse event,n(%)Neratinibmonotherapy
(N=141)
Incidenceofdiarrhea,n(%)a
Anygrade 104(73.8)
Grade3 31(22.0)
Actiontakenwithneratinib,n(%)
Permanentdiscontinuation 4(2.8)
Dosereduction 2(1.4)
Temporaryhold 21(14.9)
Seriousdiarrhea(hospitalizedorimportant medicalevent) 15(10.6)
Median(range)numberofgrade3episodesofdiarrhea perpatient 1(1–12)
Median (range)timetofirstgrade3diarrhea,days 10(4–87)
Median(range)durationofgrade3diarrheaperepisode,days 2(1–18)
aNograde4/5diarrheareported 21
AgreementbetweenlocalandcentralassessmentofHER2mutations
1Chengetal.JMol Diagn 2015;17:251–642HER2 single-genehybridcaptureresearch-use-onlyassay(MSKCC)
• >98%concordancewasobservedbetweenlocalandcentralHER2mutationassaysEnrollmentassay(n=124)
Localtest(n=96)
ArchivalFFPEtumor(MSK-IMPACT1)
(n=28)
Centraltesting(retrospective)
ArchivalFFPEtumor(MSK-IMPACT1)
98%(48/49) N/A
ScreeningcfDNA(RUOassay2)
100%(60/60)
100%(20/20)
23
PlasmactDNA attimeofneratinibclinicalprogressionrevealsacquiredHER2 (T798I)gatekeepermutationthatinducesresistance
Hankeretal.AdvancedOnlinePublication;doi:10.1158/2159-8290;CancerDiscovery2017
Progressiononneratinib
Responsetocombination
FULVESTRANTNERATINIB
AROMATASEINHIBITORS
201520142013201220112010
FulvestrantaddedSUMMIT
trial
Chestwallrecurrence
Bonemets
Skinmets
ER+/HER2–diagnosed
12/2014 1/2015
Baselineskinmets
Responsetoneratinib
4/2016 6/2016
SkinmettumorFFPENGS:L869Ractivatingmutation
PlasmactDNA Guardant360T798Igatekeepermutation
PD
2016
Conclusions
24
• Neratinibactivitywasinfluencedbybothtumorlineageandmutationtype:
– Breastcancer:single-agentactivityobserved.Combinationwithfulvestrant inER+diseaseunderway
– Biliarycancerandcervicalcancer:preliminarysingle-agentactivity;enrollmentongoing
– Lungcancer:responseratelowbutpromisingprolongeddiseasestabilizationinheavily-pretreatedpatients
– Colorectalcancerandbladdercancer,andHER3 cohort:insufficientsingle-agentactivity
– Mutationclass:missensemutationsappearmoresensitivecomparedwithexon20insertions,althoughcomparisonpartiallyconfoundedbytumor-lineageassociations
• Single-agentneratinibshowsactivityinsomecohorts;combinationsmaybeneededtoimproveactivityanddurability(similartoHER2-targetedtherapyinHER2-amplifiedtumors)
• NeratinibsafetyprofileconsistentwithpreviousreportsinmetastaticHER2-amplifiedtumors
– Diarrheawasnotatreatment-limitingtoxicitywithanti-diarrhealprophylaxis